Barclays analyst Glen Santangelo initiated coverage of Cardinal Health (CAH) with an Overweight rating and $243 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Unusually active option classes on open December 8th
- Cardinal Health price target raised to $224 from $190 at Morgan Stanley
- Cardinal Health Elects Board, Approves Executive Compensation
- Cardinal Health price target raised to $210 from $170 at Mizuho
- Cardinal Health price target raised to $220 from $190 at Jefferies